As a health-care provider, you may find it beneficial to offer support materials to your patients. Provided below are in-office educational materials designed to support your efforts as you educate parents about the benefits of immunizing their adolescent children against meningococcal disease.
As more materials become available, they will be posted here for downloading and printing.
Vaccine Information Sheet (VIS)
Click here to print a copy.
Important Safety Information
Indication
Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by N meningitidis serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent N meningitidis serogroup B disease.
Safety Information
The most common local and systemic adverse reactions to Menactra vaccine include injection site pain, redness, and induration (all age groups); irritability, crying, drowsiness, loss of appetite, and diarrhea (infants and children); headache, fatigue, and malaise (adolescents and adults). Other adverse reactions may occur.
Menactra vaccine is contraindicated in persons with known hypersensitivity to any component of the vaccine. Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of Menactra vaccine. The decision to give Menactra vaccine should take into account the potential benefits and risks. GBS has been reported in temporal relationship following administration of Menactra vaccine. Vaccination with Menactra vaccine may not protect all individuals
Before administering Menactra vaccine, please see accompanying full Prescribing Information.
© 2011 Sanofi Pasteur Inc.
References | Privacy Policy | Legal Notice
Prescribing Information